GSK
761 hedge funds and large institutions have $8.05B invested in GSK in 2016 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 211 increasing their positions, 327 reducing their positions, and 80 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
761
Holders Change
+21
Holders Change %
+2.84%
% of All Funds
19.05%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.18%
New
109
Increased
211
Reduced
327
Closed
80
Calls
$154M
Puts
$137M
Net Calls
+$16.3M
Net Calls Change
-$52.8M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$88.8M |
| 2 |
Two Sigma Advisers
New York
|
+$87.8M |
| 3 |
Renaissance Technologies
New York
|
+$83M |
| 4 |
D.E. Shaw & Co
New York
|
+$64.2M |
| 5 |
Millennium Management
New York
|
+$49.2M |
Top Sellers
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$195M |
| 2 |
JPMorgan Chase & Co
New York
|
-$83.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$72M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$45.9M |
| 5 |
Neuberger Berman Group
New York
|
-$32.9M |
